A detailed history of Yousif Capital Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Yousif Capital Management, LLC holds 38,602 shares of NBIX stock, worth $4.84 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
38,602
Previous 43,505 11.27%
Holding current value
$4.84 Million
Previous $5.99 Million 25.8%
% of portfolio
0.05%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$114.58 - $153.15 $561,785 - $750,894
-4,903 Reduced 11.27%
38,602 $4.44 Million
Q2 2024

Jul 31, 2024

SELL
$130.86 - $143.19 $386,953 - $423,412
-2,957 Reduced 6.36%
43,505 $5.99 Million
Q1 2024

Apr 26, 2024

SELL
$130.4 - $143.74 $45,118 - $49,734
-346 Reduced 0.74%
46,462 $6.41 Million
Q4 2023

Feb 01, 2024

SELL
$106.07 - $132.76 $39,245 - $49,121
-370 Reduced 0.78%
46,808 $6.17 Million
Q3 2023

Oct 30, 2023

SELL
$94.02 - $117.1 $240,221 - $299,190
-2,555 Reduced 5.14%
47,178 $5.31 Million
Q2 2023

Aug 02, 2023

SELL
$89.53 - $104.87 $111,554 - $130,668
-1,246 Reduced 2.44%
49,733 $4.69 Million
Q1 2023

May 02, 2023

BUY
$94.11 - $123.02 $16,939 - $22,143
180 Added 0.35%
50,979 $5.16 Million
Q4 2022

Jan 09, 2023

BUY
$106.72 - $127.06 $117,498 - $139,893
1,101 Added 2.22%
50,799 $0
Q3 2022

Nov 04, 2022

SELL
$92.03 - $107.81 $421,865 - $494,201
-4,584 Reduced 8.44%
49,698 $5.28 Million
Q2 2022

Aug 01, 2022

BUY
$75.79 - $100.07 $170,906 - $225,657
2,255 Added 4.33%
54,282 $5.29 Million
Q1 2022

May 12, 2022

BUY
$72.45 - $94.81 $120,049 - $157,100
1,657 Added 3.29%
52,027 $4.88 Million
Q4 2021

Jan 31, 2022

BUY
$79.65 - $106.22 $4.01 Million - $5.35 Million
50,370 New
50,370 $4.29 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.